#1 Clinical Trials Search in Europe

Deferoxamine

Deferoxamine, also known as Desferal, is a medication primarily used to treat iron overload conditions. However, recent clinical trials have expanded its potential applications to various medical conditions, including brain hemorrhages, diabetic foot ulcers, and COVID-19. This article will explore the diverse uses of Deferoxamine in ongoing clinical trials and its potential benefits for patients with different health conditions.

Table of Contents

What is Deferoxamine?

Deferoxamine, also known by its brand name Desferal or its alternative spelling Desferrioxamine, is a medication primarily used to treat iron overload in the body[1]. It belongs to a class of drugs called iron chelators, which means it binds to excess iron in the body and helps remove it[2].

How Deferoxamine Works

Deferoxamine works by binding to excess iron in the body, forming a stable complex that can be easily excreted through urine or feces. This process, known as chelation, helps reduce the amount of iron stored in various organs and tissues[1]. By removing excess iron, deferoxamine can help prevent or reduce the damage caused by iron accumulation in vital organs such as the heart, liver, and brain[3].

Medical Conditions Treated with Deferoxamine

Deferoxamine is used to treat several medical conditions, including:

  • Thalassemia: A genetic blood disorder that causes anemia and iron overload due to frequent blood transfusions[2]
  • Acute Iron Poisoning: In cases of accidental iron overdose[1]
  • Myelodysplastic Syndrome: A group of blood disorders that can lead to iron overload[1]
  • Sickle Cell Disease: Another genetic blood disorder that may require frequent blood transfusions, leading to iron overload[1]

Administration Methods

Deferoxamine can be administered in several ways, depending on the patient’s condition and treatment plan:

  • Intravenous (IV) infusion: The medication is given directly into a vein over a period of time, usually 8-12 hours[1]
  • Subcutaneous injection: The medication is injected under the skin, often using a small pump for continuous administration[4]
  • Intramuscular injection: In some cases, it may be injected into a muscle[1]

The dosage and duration of treatment vary depending on the patient’s condition, age, and response to therapy. It’s important to follow your doctor’s instructions carefully when using deferoxamine.

Potential Side Effects

Like all medications, deferoxamine can cause side effects. Some potential side effects include:

  • Injection site reactions (redness, swelling, pain)[5]
  • Allergic reactions (rare but can be serious)[5]
  • Visual or auditory changes (changes in vision or hearing)[5]
  • Respiratory issues (in rare cases)[5]

It’s important to report any unusual symptoms to your healthcare provider promptly.

Ongoing Research and Potential New Applications

Researchers are exploring the potential use of deferoxamine in treating other conditions:

  • Brain Hemorrhage: Studies are investigating whether deferoxamine can help reduce brain damage after a hemorrhagic stroke (bleeding in the brain)[6]
  • COVID-19: Some researchers are studying if deferoxamine could help reduce the severity of COVID-19 symptoms[7]
  • Wound Healing: There’s ongoing research into whether deferoxamine could improve wound healing in patients with diabetic foot ulcers[8]
  • Heart Protection: Studies are looking at whether deferoxamine can help protect the heart in patients undergoing certain medical procedures[3]

It’s important to note that these are areas of ongoing research, and deferoxamine is not currently approved for these uses. Always consult with your healthcare provider about the most appropriate treatments for your condition.

Condition Trial Phase Administration Method Key Outcomes Measured
Iron Overload in Thalassemia Not specified Subcutaneous injection Ferritin levels, Hemoglobin levels, Drug side effects
Intracerebral Hemorrhage Phase II Intravenous infusion Modified Rankin Scale score, Adverse events
COVID-19 Not specified Intravenous infusion All-cause mortality, Clinical manifestations, Length of hospitalization
Aneurysmal Subarachnoid Hemorrhage Not specified Intravenous infusion Utility-weighted modified Rankin Scale, Cognitive function, Incidence of delayed cerebral ischemia
Diabetic Foot Ulcer Not specified Topical gel application Wound healing rate, Number of patients with intact skin healing

FAQ

  • What is Deferoxamine primarily used for? Deferoxamine is primarily used to treat iron overload conditions, such as those caused by frequent blood transfusions in patients with thalassemia or other blood disorders.
  • How is Deferoxamine administered in clinical trials? In clinical trials, Deferoxamine is administered through various routes, including intravenous infusion, subcutaneous injection, and in some cases, as a topical gel. The dosage and duration of treatment vary depending on the specific condition being studied.
  • What new potential applications of Deferoxamine are being explored in clinical trials? Clinical trials are exploring the use of Deferoxamine in treating conditions such as intracerebral hemorrhage, aneurysmal subarachnoid hemorrhage, acute ischemic stroke, COVID-19, and diabetic foot ulcers.
  • How might Deferoxamine help in brain hemorrhage cases? Researchers believe that Deferoxamine may help reduce brain injury in hemorrhage cases by chelating (binding and removing) excess iron, which can accumulate in the brain after bleeding and contribute to further damage.
  • Are there any potential side effects of Deferoxamine being monitored in these trials? Yes, clinical trials are closely monitoring for potential side effects of Deferoxamine, including allergic reactions, hypotension, visual or auditory changes, and respiratory complications. The safety and tolerability of the drug are key aspects being evaluated in these studies.

Ongoing Clinical Trials on Deferoxamine

  • Study comparing Custodiol-N and Custodiol organ preservation solutions for heart transplantation in children

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Organ Preservation in Kidney, Liver, and Pancreas Transplants Using Custodiol-N Solution Compared to a Drug Combination for Transplant Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study Comparing Custodiol-N and Custodiol for Heart Surgery in Children with Congenital Heart Defects

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Liver Transplantation: Comparing Custodiol-N Solution with a Drug Combination for Organ Preservation in Patients Undergoing Liver Transplant Surgery

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Chelation therapy: A medical treatment that involves the use of drugs (chelators) to remove heavy metals or other toxins from the body. Deferoxamine is an example of a chelating agent used to remove excess iron.
  • Iron overload: A condition where excess iron builds up in the body, potentially causing damage to organs such as the liver and heart. It can occur due to repeated blood transfusions or certain genetic disorders.
  • Intracerebral hemorrhage: A type of stroke caused by bleeding within the brain tissue, which can lead to brain damage and disability.
  • Aneurysmal subarachnoid hemorrhage: A life-threatening type of stroke caused by bleeding into the space surrounding the brain, often due to a ruptured aneurysm.
  • Thalassemia: A group of inherited blood disorders characterized by decreased hemoglobin production, often requiring regular blood transfusions which can lead to iron overload.
  • Hypoxia-inducible factor 1 (HIF-1): A protein that plays a crucial role in cellular responses to low oxygen levels (hypoxia). It is being studied in relation to wound healing and other conditions.
  • Modified Rankin Scale (mRS): A commonly used scale for measuring the degree of disability or dependence in daily activities of people who have suffered a stroke or other neurological disability.

References

  1. https://clinicaltrials.gov/study/NCT00658411
  2. https://clinicaltrials.gov/study/NCT01369719
  3. https://clinicaltrials.gov/study/NCT00800761
  4. https://clinicaltrials.gov/study/NCT00777140
  5. https://clinicaltrials.gov/study/NCT01662895
  6. https://clinicaltrials.gov/study/NCT02175225
  7. https://clinicaltrials.gov/study/NCT04333550
  8. https://clinicaltrials.gov/study/NCT03137966